Enable JavaScript to visit this website.

TEST

HER2- MBC

PATIENTS WHO ARE ELIGIBLE FOR SINGLE-AGENT THERAPY

FOR A gBRCA MUTATION1

NCCN BREAST CANCER TREATMENT GUIDELINES

nccn-logo

RECOMMENDED DURING THE WORKUP FOR RECURRENT OR STAGE IV DISEASE

For patients with HER2-negative disease eligible for single-agent therapy, strongly consider germline BRCA 1/2 testing1

LEARN MORE AT NCCN.ORG

AN ESTIMATED 154,000 WOMEN WERE LIVING WITH MBC IN THE US IN 20172

IN A REAL-WORLD RETROSPECTIVE ANALYSIS OF 11,542 HR+/HER2-
AND TNBC MBC PATIENTS, 2011-2017 TESTING RATE DATA SHOW

ONLY

~22%

OF ADULT
TNBC
MBC
PATIENTS

~14%

OF ADULT
HR+/HER2-
MBC PATIENTS

WERE TESTED FOR gBRCA MUTATIONS3

COMMON TRAITS

Of patients with a gBRCA mutation

  • TNBC disease4
  • Female5
  • Less than 45 years of age4
  • Ashkenazi Jewish, African, or Hispanic descent4,6,7
  • Family history of breast or ovarian cancer4

LESSER-KNOWN TRAITS

Of patients with a gBRCA mutation

  • HR+/HER2- disease4
  • Male breast cancer in family5
  • Over 45 years of age4

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed April 23, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26(6):809-815. 3. Quek R, Mardekian J. Real-world clinical outcomes and treatment patterns among metastatic breast cancer (MBC) patients with germline BRCA mutation (gBRCAmut). J Clin Oncol. In press. 4. Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460-1468. 5. National Institutes of Health. National Cancer Institute. BRCA mutations: cancer risk and genetic testing. What are BRCA1 and BRCA2? National Institutes of Health Web site. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#q5. Accessed May 10, 2018. 6. Pal T, Bonner D, Cragun D, et al. A high frequency of BRCA mutations in young black women with breast cancer from Florida. Cancer. 2015;121(23):4173-4180. 7. John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA. 2007;298(24):2869-2876.

You are now leaving
Test4gBRCAm.com

You are now leaving Test4gBRCAm.com. Links to all outside Web sites are provided as a convenience to our visitors and do not imply a recommendation by Pfizer. Pfizer accepts no responsibility or liability for content or services of other Web sites.

You are now leaving Test4gBRCAm.com to enter a website neither owned nor operated by Pfizer. Links to all outside sites are provided as a resource to our visitors and do not imply an endorsement or recommendation of a particular physician by Pfizer, nor an endorsement of any Pfizer product by a telehealth provider or any physician.

Pfizer accepts no responsibility or liability for the content or services of other websites. All prescription decisions are at the sole discretion of the healthcare provider, based on the patient’s needs.

Back